Aeolus Pharmaceuticals’ AEOL 10150 effective against mustard gas exposure

Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board:AOLS) reported that researchers from National Jewish Health and Lovelace Respiratory Research Institute have completed a series of preliminary studies demonstrating that AEOL 10150 protects lungs from whole mustard gas exposure in rats. Data were presented at the Regional CounterACT Countermeasures Against Chemical Threats Conference in Albuquerque, NM. There are currently no effective treatments for mustard gas exposure and AEOL 10150 is a major focus of a sponsored research grant awarded by the NIH Counteract program to National Jewish Health to identify an effective treatment. Sulfur mustards have been used in warfare since WWI and still pose a significant threat to civilian and military personnel. Mustard gas exposure can cause significant blistering of the skin as well as respiratory injury and fibrosis.

“We are very impressed with the robust effects of AEOL 10150 in rescuing the lung against the deleterious effects of sulfur mustard vapor,” stated Dr. Carl White, pediatric pulmonologist at National Jewish and Director of the CounterACT Center of Excellence in Denver. “These data affirm our earlier studies where AEOL 10150 protected the lung against the half-mustard, 2-chloroethyl ethylsufide.”

Source: Aeolus Pharmaceuticals, Inc.